Matches in Wikidata for { <http://www.wikidata.org/entity/Q65381453> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q65381453 description "clinical trial" @default.
- Q65381453 description "ensayu clínicu" @default.
- Q65381453 description "klinisch onderzoek" @default.
- Q65381453 description "клінічне випробування" @default.
- Q65381453 name "Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer" @default.
- Q65381453 name "Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer" @default.
- Q65381453 type Item @default.
- Q65381453 label "Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer" @default.
- Q65381453 label "Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer" @default.
- Q65381453 prefLabel "Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer" @default.
- Q65381453 prefLabel "Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer" @default.
- Q65381453 P1132 Q65381453-D274070A-E324-4DE1-B853-BB66E7F28EFE @default.
- Q65381453 P1476 Q65381453-77CA7D5B-A167-483B-842B-B89E12FB8FF0 @default.
- Q65381453 P17 Q65381453-0F46846E-1112-4B9B-A0C2-062E2F77DDFC @default.
- Q65381453 P17 Q65381453-50628691-10C4-44F6-A74D-859F1D2A9014 @default.
- Q65381453 P17 Q65381453-53271C7F-FDB3-4AC2-9A6F-DC18CA300D6C @default.
- Q65381453 P17 Q65381453-69D31795-88F7-4239-BFF6-D48ADE4DEB21 @default.
- Q65381453 P17 Q65381453-7615F161-AED4-49AB-88E5-8A7364C2009D @default.
- Q65381453 P1813 Q65381453-F8F6E895-E63C-448B-9091-2519C5C3E1C3 @default.
- Q65381453 P2899 Q65381453-C8970086-50F3-45E2-B376-042AB94C48D6 @default.
- Q65381453 P3098 Q65381453-AFE6E1A4-8686-4E5E-98C9-A80719A336B4 @default.
- Q65381453 P31 Q65381453-659120E4-77BB-4C87-B16F-5D9A55A44D8B @default.
- Q65381453 P4135 Q65381453-387F359D-3121-4B9A-AF61-4E198EEADA51 @default.
- Q65381453 P580 Q65381453-C015CDB8-1028-4DB7-90D2-AE4A3B844ADC @default.
- Q65381453 P582 Q65381453-1E2FE7D6-6626-467B-97ED-363AADC2D0BD @default.
- Q65381453 P6099 Q65381453-4379622B-4F6D-4D34-9B6C-0BCE106643F4 @default.
- Q65381453 P8363 Q65381453-465C6AD6-ED71-40B1-9CD6-2EB7B29F5E3E @default.
- Q65381453 P1132 "+54" @default.
- Q65381453 P1476 "A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer" @default.
- Q65381453 P17 Q145 @default.
- Q65381453 P17 Q183 @default.
- Q65381453 P17 Q30 @default.
- Q65381453 P17 Q34 @default.
- Q65381453 P17 Q408 @default.
- Q65381453 P1813 "ICEBERG 1" @default.
- Q65381453 P2899 "+18" @default.
- Q65381453 P3098 "NCT00494234" @default.
- Q65381453 P31 Q30612 @default.
- Q65381453 P4135 "+130" @default.
- Q65381453 P580 "2007-06-15T00:00:00Z" @default.
- Q65381453 P582 "2009-02-27T00:00:00Z" @default.
- Q65381453 P6099 Q42824440 @default.
- Q65381453 P8363 Q78089383 @default.